Skip to main content
. 2021 Aug 5;118(10):2367–2384. doi: 10.1093/cvr/cvab263

Figure 1.

Figure 1

The association of TMAO levels with thromboembolic clinical outcomes in patients on anti-platelets in the Cleveland and Swiss ACS Cohorts. Kaplan–Meier estimates and the risk of incident MACE (MI, stroke, or death) over follow-up periods ranked by quartiles of TMAO levels in (A) GeneBank patients with anti-platelet therapy (aspirin or ADP-receptor antagonists) as well as (C) Swiss ACS patients with dual anti-platelet therapy. P-values by log rank test are indicated. Forest plots indicating the risks of (B) incident MACE at 3 years for GeneBank and (D) at 1 year for Swiss ACS subjects stratified by quartiles of TMAO levels (unadjusted in grey), multivariable Cox model for HR included adjustments for traditional risk factors including age, gender, hypertension, smoking, diabetes, HDL, LDL, TG (adjustment 1, in black); and traditional risk factors plus renal function (adjustment 2, in red), as described in Section 2. The 5–95% CI is indicated by line length.